Consistently, JAK2 kinase inhibitors, such as AG490, strongly reduce c-Myc expression in CML cells and induce apoptosis [14, 16], thus representing promising molecular tools to bypass Imatinib resistance in CML [17–19]. This evidence concerns the gene MYC and chronic myelogenous leukemia, BCR-ABL1 positive.